Cargando…

Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective

Melanoma represents an increasing public health burden with extensive unmet needs in Latin America (LA). A mutation in the BRAF gene is present in approximately 50% of all melanomas in White populations and is a target of precision medicine, with the potential to dramatically improve patient outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Salman, Pamela, de Melo, Andreia Cristina, Rico-Restrepo, Mariana, Rodriguez, Jeronimo, Russi, Andrea, Schmerling, Rafael Aron, Zambrano, Angela, Cinat, Gabriela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043339/
https://www.ncbi.nlm.nih.gov/pubmed/36998456
http://dx.doi.org/10.3389/fonc.2023.1032300
_version_ 1784913124658249728
author Salman, Pamela
de Melo, Andreia Cristina
Rico-Restrepo, Mariana
Rodriguez, Jeronimo
Russi, Andrea
Schmerling, Rafael Aron
Zambrano, Angela
Cinat, Gabriela
author_facet Salman, Pamela
de Melo, Andreia Cristina
Rico-Restrepo, Mariana
Rodriguez, Jeronimo
Russi, Andrea
Schmerling, Rafael Aron
Zambrano, Angela
Cinat, Gabriela
author_sort Salman, Pamela
collection PubMed
description Melanoma represents an increasing public health burden with extensive unmet needs in Latin America (LA). A mutation in the BRAF gene is present in approximately 50% of all melanomas in White populations and is a target of precision medicine, with the potential to dramatically improve patient outcomes. Thus, increased access to BRAF testing and therapy is LA must be explored. At a multi-day conference, a panel of Latin American experts in oncology and dermatology were provided with questions to address the barriers limiting access to testing for BRAF mutation in patients with melanoma in LA, who may be eligible for targeted therapy to improve their prognosis. During the conference, responses were discussed and edited until a consensus on addressing the barriers was achieved. Identified challenges included ignorance of BRAF-status implications, limited human and infrastructural resources, affordability and reimbursement, fragmented care delivery, pitfalls in the sample journey, and lack of local data. Despite the clear benefits of targeted therapies for BRAF-mutated melanoma in other regions, there is no clear path to prepare LA for a sustainable personalized medicine approach to this disease. Due to melanoma’s time-sensitive nature, LA must aim to provide early access to BRAF testing and consider mutational status within treatment decision making. To this end, recommendations are provided and include establishing multidisciplinary teams and melanoma referral centers and improving access to diagnosis and treatment.
format Online
Article
Text
id pubmed-10043339
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100433392023-03-29 Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective Salman, Pamela de Melo, Andreia Cristina Rico-Restrepo, Mariana Rodriguez, Jeronimo Russi, Andrea Schmerling, Rafael Aron Zambrano, Angela Cinat, Gabriela Front Oncol Oncology Melanoma represents an increasing public health burden with extensive unmet needs in Latin America (LA). A mutation in the BRAF gene is present in approximately 50% of all melanomas in White populations and is a target of precision medicine, with the potential to dramatically improve patient outcomes. Thus, increased access to BRAF testing and therapy is LA must be explored. At a multi-day conference, a panel of Latin American experts in oncology and dermatology were provided with questions to address the barriers limiting access to testing for BRAF mutation in patients with melanoma in LA, who may be eligible for targeted therapy to improve their prognosis. During the conference, responses were discussed and edited until a consensus on addressing the barriers was achieved. Identified challenges included ignorance of BRAF-status implications, limited human and infrastructural resources, affordability and reimbursement, fragmented care delivery, pitfalls in the sample journey, and lack of local data. Despite the clear benefits of targeted therapies for BRAF-mutated melanoma in other regions, there is no clear path to prepare LA for a sustainable personalized medicine approach to this disease. Due to melanoma’s time-sensitive nature, LA must aim to provide early access to BRAF testing and consider mutational status within treatment decision making. To this end, recommendations are provided and include establishing multidisciplinary teams and melanoma referral centers and improving access to diagnosis and treatment. Frontiers Media S.A. 2023-03-14 /pmc/articles/PMC10043339/ /pubmed/36998456 http://dx.doi.org/10.3389/fonc.2023.1032300 Text en Copyright © 2023 Salman, de Melo, Rico-Restrepo, Rodriguez, Russi, Schmerling, Zambrano and Cinat https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Salman, Pamela
de Melo, Andreia Cristina
Rico-Restrepo, Mariana
Rodriguez, Jeronimo
Russi, Andrea
Schmerling, Rafael Aron
Zambrano, Angela
Cinat, Gabriela
Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective
title Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective
title_full Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective
title_fullStr Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective
title_full_unstemmed Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective
title_short Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective
title_sort addressing the unmet needs of patients with braf-mutated melanoma in latin america: expert perspective
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043339/
https://www.ncbi.nlm.nih.gov/pubmed/36998456
http://dx.doi.org/10.3389/fonc.2023.1032300
work_keys_str_mv AT salmanpamela addressingtheunmetneedsofpatientswithbrafmutatedmelanomainlatinamericaexpertperspective
AT demeloandreiacristina addressingtheunmetneedsofpatientswithbrafmutatedmelanomainlatinamericaexpertperspective
AT ricorestrepomariana addressingtheunmetneedsofpatientswithbrafmutatedmelanomainlatinamericaexpertperspective
AT rodriguezjeronimo addressingtheunmetneedsofpatientswithbrafmutatedmelanomainlatinamericaexpertperspective
AT russiandrea addressingtheunmetneedsofpatientswithbrafmutatedmelanomainlatinamericaexpertperspective
AT schmerlingrafaelaron addressingtheunmetneedsofpatientswithbrafmutatedmelanomainlatinamericaexpertperspective
AT zambranoangela addressingtheunmetneedsofpatientswithbrafmutatedmelanomainlatinamericaexpertperspective
AT cinatgabriela addressingtheunmetneedsofpatientswithbrafmutatedmelanomainlatinamericaexpertperspective